Back to Amber's Profile

North American English female, biopharmaceutical, , health sciences

Not Yet Rated
Voice Over • Video Narration


This is a Voice Over I recorded for the company Cassava Sciences for their new Alzheimer's drug, Sumifilam. This take represents a natural, confident and effervescent quality in my voice while delivering important and complex information.

Vocal Characteristics


English (North American)

Voice Age

Middle Aged (35-54)


Note: Transcripts are generated using speech recognition software and may contain errors.
Small phylum is a new drug for Alzheimer's disease. The drug targets a protein in the brain called Philemon A. In Alzheimer's disease, Philemon A takes on an altered shape causing neuronal dysfunction, neuro degeneration and neuro inflammation. Sima Phil um returns altered Philomene, a back to its normal shape in a randomized placebo controlled clinical trial funded by NIH Sima Phil um improved 11 biomarkers of disease pathology, neuro degeneration and neuro inflammation. These 11 biomarkers span multiple biological pathways affected in Alzheimer's disease. In multiple studies, patients treated with Sima phylum have shown potential improvements in memory assessments. These and other results suggest. Some. A phylum may slow disease progression and improve thinking and memory in patients with Alzheimer's disease.